Show simple item record

dc.contributor.authorGuan, Ruili
dc.contributor.authorPurohit, Sharad
dc.contributor.authorWang, Hongjie
dc.contributor.authorBode, Bruce
dc.contributor.authorReed, John Chip
dc.contributor.authorSteed, R. Dennis
dc.contributor.authorAnderson, Stephen W.
dc.contributor.authorSteed, Leigh
dc.contributor.authorHopkins, Diane
dc.contributor.authorXia, Chun
dc.contributor.authorShe, Jin-Xiong
dc.date.accessioned2012-10-26T16:26:58Z
dc.date.available2012-10-26T16:26:58Z
dc.date.issued2011-04-12en_US
dc.identifier.citationPLoS One. 2011 Apr 12; 6(4):e17822en_US
dc.identifier.issn1932-6203en_US
dc.identifier.pmid21532752en_US
dc.identifier.doi10.1371/journal.pone.0017822en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/648
dc.description.abstractBackground: Chemokine (C-C motif) ligand 2 (CCL2), commonly known as monocyte chemoattractant protein-1 (MCP-1), has been implicated in the pathogenesis of many diseases characterized by monocytic infiltration. However, limited data have been reported on MCP-1 in type 1 diabetes (T1D) and the findings are inconclusive and inconsistent.
dc.description.abstractMethods: In this study, MCP-1 was measured in the sera from 2,472 T1D patients and 2,654 healthy controls using a Luminex assay. The rs1024611 SNP in the promoter region of MCP-1 was genotyped for a subset of subjects (1764 T1D patients and 1323 controls) using the TaqMan-assay.
dc.description.abstractResults: Subject age, sex or genotypes of MCP-1 rs1024611SNP did not have a major impact on serum MCP-1 levels in either healthy controls or patients. While hemoglobin A1c levels did not have a major influence on serum MCP-1 levels, the mean serum MCP-1 levels are significantly higher in patients with multiple complications (mean=242 ng/ml) compared to patients without any complications (mean=201 ng/ml) (p=3.5x10^-6). Furthermore, mean serum MCP-1 is higher in controls (mean=261 ng/ml) than T1D patients (mean=208 ng/ml) (p<10^-23). More importantly, the frequency of subjects with extremely high levels (>99th percentile of patients or 955 ng/ml) of serum MCP-1 is significantly lower in the T1D group compared to the control group (odds ratio=0.11, p<10^-33).
dc.description.abstractConclusion: MCP-1 may have a dual role in T1D and its complications. While very high levels of serum MCP-1 may be protective against the development of T1D, complications are associated with higher serum MCP-1 levels within the T1D group.
dc.rightsGuan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en_US
dc.subjectResearch Articleen_US
dc.subjectBiologyen_US
dc.subjectBiochemistryen_US
dc.subjectProteinsen_US
dc.subjectPlasma Proteinsen_US
dc.subjectMedicineen_US
dc.subjectClinical Immunologyen_US
dc.subjectImmune Systemen_US
dc.subjectCytokinesen_US
dc.subjectAutoimmune Diseasesen_US
dc.subjectGenetics of the Immune Systemen_US
dc.subjectEndocrinologyen_US
dc.subjectDiabetic Endocrinologyen_US
dc.subjectDiabetes Mellitus Type 1en_US
dc.titleChemokine (C-C Motif) Ligand 2 (CCL2) in Sera of Patients with Type 1 Diabetes and Diabetic Complicationsen_US
dc.typeArticleen_US
dc.identifier.pmcidPMC3075244en_US
dc.contributor.corporatenameCenter for Biotechnology and Genomic Medicine
dc.contributor.corporatenameDepartment of Pathology
refterms.dateFOA2019-04-10T00:24:13Z
html.description.abstractBackground: Chemokine (C-C motif) ligand 2 (CCL2), commonly known as monocyte chemoattractant protein-1 (MCP-1), has been implicated in the pathogenesis of many diseases characterized by monocytic infiltration. However, limited data have been reported on MCP-1 in type 1 diabetes (T1D) and the findings are inconclusive and inconsistent.
html.description.abstractMethods: In this study, MCP-1 was measured in the sera from 2,472 T1D patients and 2,654 healthy controls using a Luminex assay. The rs1024611 SNP in the promoter region of MCP-1 was genotyped for a subset of subjects (1764 T1D patients and 1323 controls) using the TaqMan-assay.
html.description.abstractResults: Subject age, sex or genotypes of MCP-1 rs1024611SNP did not have a major impact on serum MCP-1 levels in either healthy controls or patients. While hemoglobin A1c levels did not have a major influence on serum MCP-1 levels, the mean serum MCP-1 levels are significantly higher in patients with multiple complications (mean=242 ng/ml) compared to patients without any complications (mean=201 ng/ml) (p=3.5x10^-6). Furthermore, mean serum MCP-1 is higher in controls (mean=261 ng/ml) than T1D patients (mean=208 ng/ml) (p<10^-23). More importantly, the frequency of subjects with extremely high levels (>99th percentile of patients or 955 ng/ml) of serum MCP-1 is significantly lower in the T1D group compared to the control group (odds ratio=0.11, p<10^-33).
html.description.abstractConclusion: MCP-1 may have a dual role in T1D and its complications. While very high levels of serum MCP-1 may be protective against the development of T1D, complications are associated with higher serum MCP-1 levels within the T1D group.


Files in this item

Thumbnail
Name:
pone.0017822.pdf
Size:
784.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record